Six readers
| reader | found | score |
|---|---|---|
| genetics Open Targets | genetic association 0.52 (overall 0.32) | 0.52 |
| cell type Human Protein Atlas | cell type enhanced, including brain excitatory neurons; strongest in rod photoreceptor cells | 0.75 |
| chemistry Open Targets | hard to drug | 0.00 |
| trials ClinicalTrials.gov | no Parkinson's trials on record: an open field | 1.00 |
| literature PubMed | 4 Parkinson's papers of 20 | 0.79 |
| pathways Reactome | in no curated pathway | 0.00 |
No case: the score is under the bar. Receipt 1142
Sealed predictions
- LZTS3 in dopamine neurons, braak-0.23 (p 0.545) → -0.45 (p 0.222)receipt 1149
Swarm cases
receipt 1149: LZTS3 in dopamine neurons, braak
- power
- full sample -0.28 (p 0.265, n 18), 95% CI -0.66 to +0.22. the interval is wide: not enough donors to tell.
- confounder
- adjusted for sex: -0.28 (p 0.265, n 18). does not hold up.
- composition
- dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: -0.45 (p 0.062, n 18). could be the mix.
- skeptic
- leave-one-out range -0.44 to -0.18, sign flips 0; without severely affected donors -0.28 (p 0.265, n 18). fragile.
- cell type
- strongest in astrocytes: -0.61 (p 0.0072, n 18) vs -0.28 in dopamine neurons. proposing astrocytes.
- axis
- no measure beats "tracks Braak Lewy-body stage" for LZTS3 in dopamine neurons.
follow-up registered; not confirmed in substantia nigra, an independent cohort.
follow-up LZTS3 · astrocytes · braak: substantia nigra, an independent cohort (Parkinson's or LBD vs controls) +0.55 p 0.051 (needs p < 0.0012)
Receipts
loading the receipts